This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008;26(3):181-3.

doi: 10.2165/00019053-200826030-00002.

Transparency of economic evaluations of health technologies

PMID: 18282013
DOI: 10.2165/00019053-200826030-00002

Editorial

Transparency of economic evaluations of health technologies

Joan Rovira. Pharmacoeconomics. 2008.

. 2008;26(3):181-3.

doi: 10.2165/00019053-200826030-00002.

Author

PMID: 18282013
DOI: 10.2165/00019053-200826030-00002

No abstract available

PubMed Disclaimer

Comment in

Meandering down the road to transparency.
Carswell CI, Paladino JA. Carswell CI, et al. Pharmacoeconomics. 2008;26(3):179-80. doi: 10.2165/00019053-200826030-00001. Pharmacoeconomics. 2008. PMID: 18282012 No abstract available.

Similar articles

Meandering down the road to transparency.
Carswell CI, Paladino JA. Carswell CI, et al. Pharmacoeconomics. 2008;26(3):179-80. doi: 10.2165/00019053-200826030-00001. Pharmacoeconomics. 2008. PMID: 18282012 No abstract available.
Transparency in economic evaluations.
Hill S. Hill S. Pharmacoeconomics. 2005;23(10):967-9. doi: 10.2165/00019053-200523100-00001. Pharmacoeconomics. 2005. PMID: 16235971 No abstract available.
What you don't know can't hurt you? Statistical issues and standards for medical technology evaluation.
Mullahy J. Mullahy J. Med Care. 1996 Dec;34(12 Suppl):DS124-35. Med Care. 1996. PMID: 8969321 Review. No abstract available.
Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.
Frederix GW, Haji Ali Afzali H, Dasbach EJ, Ward RL. Frederix GW, et al. Pharmacoeconomics. 2015 Aug;33(8):777-81. doi: 10.1007/s40273-015-0274-y. Pharmacoeconomics. 2015. PMID: 25827099 No abstract available.
Pharmacoeconomics: integrating economic evaluation into clinical trials.
Haycox A, Drummond M, Walley T. Haycox A, et al. Br J Clin Pharmacol. 1997 Jun;43(6):559-62. doi: 10.1046/j.1365-2125.1997.00576.x. Br J Clin Pharmacol. 1997. PMID: 9205814 Free PMC article. Review. No abstract available.

See all similar articles

Cited by

Meandering down the road to transparency.
Carswell CI, Paladino JA. Carswell CI, et al. Pharmacoeconomics. 2008;26(3):179-80. doi: 10.2165/00019053-200826030-00001. Pharmacoeconomics. 2008. PMID: 18282012 No abstract available.
When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.
Catalá-López F, Sanfélix-Gimeno G, Ridao M, Peiró S. Catalá-López F, et al. PLoS One. 2013 Jul 8;8(7):e69462. doi: 10.1371/journal.pone.0069462. Print 2013. PLoS One. 2013. PMID: 23861972 Free PMC article.
Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis.
Catalá-López F, Alonso-Arroyo A, Aleixandre-Benavent R, Ridao M, Bolaños M, García-Altés A, Sanfélix-Gimeno G, Peiró S. Catalá-López F, et al. PLoS One. 2012;7(5):e38012. doi: 10.1371/journal.pone.0038012. Epub 2012 May 29. PLoS One. 2012. PMID: 22666435 Free PMC article.

References

1. BMJ. 1996 Aug 3;313(7052):275-83 - PubMed
1. N Engl J Med. 1991 May 9;324(19):1362-5 - PubMed
1. Ann Intern Med. 1995 Jul 1;123(1):61-70 - PubMed
1. Soc Sci Med. 1997 Aug;45(4):555-62 - PubMed
1. Pharmacoeconomics. 1992 Jan;1(1):8-13 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer